Centrum Onkologii Im. Prof. Franciszka Lukaszczyka W Bydgoszczy

Centrum Onkologii Im. Prof. Franciszka Lukaszczyka is conducting a broad portfolio of studies in patients with advanced and early‑stage kidney cancer. The trials aim to test new combinations of immune checkpoint inhibitors with targeted agents, evaluate adjuvant immunotherapy after surgery, and explore biomarkers that predict response.

• Combination of PD‑1/PD‑L1 blockers with tyrosine‑kinase inhibitors
• Adjuvant therapy for post‑nephrectomy patients
• Biomarker‑driven patient selection
• Sequencing of immunotherapy and anti‑angiogenic treatment

These efforts support the development of more effective and personalized treatment options for renal cell carcinoma patients in Poland and across Europe.

The department is active in many trials for non‑small cell lung cancer, ranging from early‑stage disease treated with surgery and radiation to metastatic disease driven by specific genetic alterations. Studies evaluate novel EGFR inhibitors, immune‑based regimens, and the integration of stereotactic radiotherapy with systemic therapy.

• Targeted therapy for EGFR‑mutated tumors
• Immunotherapy combined with chemotherapy in first‑line setting
• Adjuvant immunotherapy after curative‑intent radiation
• Sequential use of checkpoint inhibitors and tyrosine‑kinase inhibitors

By addressing both molecular and immunologic pathways, the site seeks to improve survival and quality of life for patients with non‑small cell lung cancer.

A series of investigations focus on diverse subtypes of breast cancer, including HER2‑positive, hormone‑receptor positive, and triple‑negative disease. Trials test antibody‑drug conjugates, CDK4/6 inhibitors, and immune checkpoint blockade in neoadjuvant and adjuvant contexts.

• HER2‑directed antibody‑drug conjugates
• CDK4/6 inhibitor plus endocrine therapy for HR‑positive disease
• Neoadjuvant immunotherapy for triple‑negative tumors
• Combination of targeted therapy with chemotherapy in metastatic setting

These studies aim to expand treatment options and reduce recurrence risk for patients with breast cancer.

Research at the site includes trials for both hormone‑sensitive and castration‑resistant prostate cancer, with a focus on androgen deprivation strategies, novel hormonal agents, and PSMA‑based imaging to guide therapy.

• Combination of androgen deprivation therapy with novel anti‑androgens
• PSMA PET‑guided treatment planning
• Immunotherapy in metastatic castration‑resistant disease
• Evaluation of radiotherapy plus systemic therapy in high‑risk localized disease

The goal is to prolong progression‑free survival and improve overall outcomes for men with prostate cancer.

The Ambulatorium Chemioterapii runs studies on colorectal, gastric, pancreatic, biliary tract, and hepatocellular carcinoma. Trials investigate targeted agents against FGFR2b, HIF‑2α, and HER2, as well as immunotherapy approaches in advanced disease.

• FGFR2b‑targeted therapy for gastric and biliary cancers
• HER2‑directed treatment in gastro‑esophageal tumors
• Immunotherapy combined with chemotherapy for metastatic colorectal cancer
• HIF‑2α inhibitors for advanced renal and liver tumors

These programs aim to bring new therapeutic options to patients with gastrointestinal and hepatobiliary malignancies.

Clinical investigations include squamous cell carcinoma of the head and neck as well as cutaneous squamous cell carcinoma. The focus is on checkpoint inhibitor combinations, radiation‑based strategies, and biomarker‑driven patient selection.

• Checkpoint inhibitor plus radiotherapy for unresectable head‑and‑neck cancer
• Neoadjuvant immunotherapy before surgery
• Targeted therapy for HPV‑negative disease
• Adjuvant immunotherapy after resection of cutaneous SCC

The aim is to enhance cure rates and preserve organ function for individuals with head and neck or skin cancers.

A subset of trials addresses rare cancers and tumors defined by specific genetic alterations, such as VHL‑associated neoplasms, HRR‑mutated prostate cancer, and HIF‑2α driven malignancies. Research evaluates novel inhibitors and combination regimens tailored to these molecular signatures.

• HIF‑2α inhibitors for VHL‑related tumors
• PARP inhibitor strategies for HRR‑mutated prostate cancer
• Targeted therapy for KRAS G12C‑mutated lung cancer
• Combination regimens for neuroendocrine tumors

These efforts reflect a commitment to precision oncology for patients with rare or molecularly defined cancers.